Literature DB >> 22331811

Synergistic cytotoxic effect of the microtubule inhibitor marchantin A from Marchantia polymorpha and the Aurora kinase inhibitor MLN8237 on breast cancer cells in vitro.

J Sophie Jensen1, Sesselja Omarsdottir, Jenny B Thorsteinsdottir, Helga M Ogmundsdottir, Elin S Olafsdottir.   

Abstract

Macrocyclic bisbibenzyls are a class of characteristic compounds, exclusively produced by liverworts. They are attracting increasing attention due to their wide range of biological activities, including antibacterial, antifungal, and antioxidative properties as well as cytotoxicity. Marchantin A is a cyclic bisbibenzyl that has previously been isolated from Marchantia polymorpha and other liverwort species and has been shown to exert cytotoxic effects. In the present study we found that the Icelandic M. polymorpha species produces marchantin A and through an in vitro cell growth inhibition assay, marchantin A was shown to induce a reduction in cell viability of breast cancer cell lines A256 (IC₅₀ = 5.5 µM), MCF7 (IC₅₀ = 11.5 µM), and T47D (IC₅₀ = 15.3 µM). The effect was considerably increased in all cell lines in a synergistic manner when the Aurora-A kinase inhibitor MLN8237 was added simultaneously. Fluorescence microscopy confirmed the antimicrotubular effect of marchantin A, and cell cycle analysis indicated enhanced cell division failure when combining this mitotic-spindle inhibitor with the checkpoint modulator. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331811     DOI: 10.1055/s-0031-1298230

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  5 in total

1.  Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.

Authors:  Mari Kogiso; Lin Qi; Frank K Braun; Sarah G Injac; Linna Zhang; Yuchen Du; Huiyuan Zhang; Frank Y Lin; Sibo Zhao; Holly Lindsay; Jack M Su; Patricia A Baxter; Adekunle M Adesina; Debra Liao; Mark G Qian; Stacey Berg; Jodi A Muscal; Xiao-Nan Li
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

2.  The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.

Authors:  Jin-Ping Li; Yin-Xue Yang; Qi-Lun Liu; Shu-Ting Pan; Zhi-Xu He; Xueji Zhang; Tianxin Yang; Xiao-Wu Chen; Dong Wang; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-16       Impact factor: 4.162

3.  Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers.

Authors:  Margret Aradottir; Sigridur T Reynisdottir; Olafur A Stefansson; Jon G Jonasson; Asgerdur Sverrisdottir; Laufey Tryggvadottir; Jorunn E Eyfjord; Sigridur K Bodvarsdottir
Journal:  J Pathol Clin Res       Date:  2014-11-07

4.  Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.

Authors:  Vladislav Korobeynikov; Michelle Borakove; Yayi Feng; William M Wuest; Alex B Koval; Anna S Nikonova; Ilya Serebriiskii; Jonathan Chernoff; Virginia F Borges; Erica A Golemis; Elena Shagisultanova
Journal:  Breast Cancer Res Treat       Date:  2019-06-28       Impact factor: 4.872

5.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Authors:  Michael Krauthammer; Yong Kong; Byung Hak Ha; Perry Evans; Antonella Bacchiocchi; James P McCusker; Elaine Cheng; Matthew J Davis; Gerald Goh; Murim Choi; Stephan Ariyan; Deepak Narayan; Ken Dutton-Regester; Ana Capatana; Edna C Holman; Marcus Bosenberg; Mario Sznol; Harriet M Kluger; Douglas E Brash; David F Stern; Miguel A Materin; Roger S Lo; Shrikant Mane; Shuangge Ma; Kenneth K Kidd; Nicholas K Hayward; Richard P Lifton; Joseph Schlessinger; Titus J Boggon; Ruth Halaban
Journal:  Nat Genet       Date:  2012-07-29       Impact factor: 38.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.